Condition 1: sever local reaction following immunization. Condition 2: sever local reaction following immunization. Infection following immunization Other complications following immunization, not elsewhere classified
Conditions
Interventions
Intervention 1: DTP vaccine is administrated by type B syringe. Intervention 2: DTP vaccine is administrated by type A syringe.
DTP vaccine is administrated by type B syringe
DTP vaccine is administrated by type A syringe
Sponsors
Shahroud University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 6 Years
Inclusion criteria
Inclusion criteria: All children who are eligible for DTP vaccination can be registered in this study. every eligible child is not enrolled in study If DTP vaccination is contraindicated, his/her parents denied to sign informed consent or the child is not accessible for follow up of AEFI (adverse effects following immunization ).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythema. Timepoint: days 2, 4 and 6 following immunization. Method of measurement: By health care professional and/or physician.;Oedema. Timepoint: days 2, 4 and 6 following immunization. Method of measurement: By health care professional and/or physician.;Pain. Timepoint: days 2, 4 and 6 following immunization. Method of measurement: By health care professional and/or physician.;Fever. Timepoint: days 2, 4 and 6 following immunization. Method of measurement: By health care professional and/or physician. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sever local reaction AND Injection-Site Abscess. Timepoint: Days 2, 4, and 6 after immunization. Method of measurement: By health care professional and/or physician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMansooreh Fateh, MD, MPH
Shahroud university of Medical Sciences
Outcome results
None listed